Advanced Medical Isotopes Corporation Announces Three Year Business Strategy Focused On Transitioning From A Development-Stage Company To An Operating Company

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

KENNEWICK, Wash., Dec. 2, 2013 (GLOBE NEWSWIRE) -- Advanced Medical Isotope Corporation (“AMIC”) (OTCBB:ADMD), a company engaged in the development, production and distribution of medical isotopes, today announced that its Board of Directors has approved a three year business strategy focused on transitioning to full operations in 2014, following the anticipated receipt of FDA clearance for its patented brachytherapy cancer product, Yttrium-90 RadioGel™.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC